spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cisplatin 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 21 Mar 2024
Renibus Announces Leadership Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jul 2023
Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jul 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Mar 2021
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2020
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
Biopharmaceuticals Oncology Neurology Licensing
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI(R) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Apr 2018
Cumberland Pharmaceuticals Expands into Oncology Support
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2017
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer with Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 11 Oct 2016
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Devices Oncology
 HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2016
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2016
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 13 Jul 2015
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jan 2015
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin(TM) Platform for Cancer Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2013
Senhwa Biosciences Raises $17M Series B
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2011
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2011
APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2010
Sagent Pharmaceuticals Announces FDA Approval of Granisetron Hydrochloride Injection, USP
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2010
Study Reveals TomoTherapy(R) Technology Plays Key Role in Enabling Concurrent Chemo-Radiation Treatments for Lung Cancer
Devices Oncology
 HSMN NewsFeed - 23 Feb 2010
BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung Cancer
Devices Oncology
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2009
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 May 2009
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticasl Oncology Regulatory
 HSMN NewsFeed - 18 May 2009
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2009
IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jan 2009
A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2008
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2008
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jul 2008
APP Pharmaceuticals Receives Final Approvals for Additional Dosages of Granisetron Hydrochloride Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2008
Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2008
Multiple Studies Demonstrate the Use of Hyperthermia Therapy in Treating Pancreatic Cancer
Devices Oncology
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2008
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Hawthorn Pharmaceuticals, Inc. Receives FDA Approval on Granisol(TM) Oral Solution
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2008
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2008
FDA Approves EMEND(R) (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jan 2008
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jan 2008
Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Nov 2007
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Oct 2007
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2007
New Publication Report -- Hyperthermia Plus Cisplatin as a Treatment for Recurrent Cervical Carcinoma for Previously Irradiated Patients
Devices Oncology
 HSMN NewsFeed - 1 Oct 2007
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2007
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2007
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Point Therapeutics Update
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 27 Jun 2007
Taxotere(R) (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Transave, Inc. Appoints Mich Soga as Chief Financial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Point Therapeutics Reduces Costs by Cutting Work Force
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Esophageal and Gastric Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Head and Neck Cancers Guidelines
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2007
SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2007
Coley Pharmaceutical Group Announces Completion of Patient Enrollment in Pfizer's Two Pivotal Phase III NSCLC Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2007
Barr Receives Tentative Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
MedImmune Announces District Court's Rejection of Sun Pharmaceutical's Motion to End Litigation Regarding Generic Amifostine
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2007
Poniard Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase 3 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2006
Poniard Announces Positive Interim Survival Results from Ongoing Phase 2 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
EpiCept Announces IND Filing of Novel Compound with Potent Apoptotic and Tumor Selective Vascular Disruptive Activity for Treatment of Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2006
FDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2006
Point Therapeutics Receives Fast Track Designation for Talabostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2006
Marshall Edwards Achieves Special Protocol Assessment and Agreement With FDA on Phase III (Ovature Study) of Phenoxodiol as a Chemosensitizing Agent in Women With Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  

 Additional items found! 186

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 186 additional stories matching:
cisplatin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.